Performance characteristics of commercial immunoassays for the detection of IgG and IgM antibodies to b2 glycoprotein i and an initial assessment of newly developed reference materials for assay calibration

American Journal of Clinical Pathology

Volumn 145, Issue 6, 2016, Pages 796-805

  Willis, Rohan ^a   Pierangeli, Silvia S ^a   Jaskowski, Troy D ^b   Malmberg, Elisabeth ^b   Guerra, Marta ^c   Salmon, Jane E ^c   Petri, Michelle ^d   Branch, D Ware ^e   Tebo, Anne E ^b,e  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^c HOSPITAL FOR SPECIAL SURGERY   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Antibodies; Antiphospholipid syndrome; B2 glycoprotein I; Harmonization; Immunoassays; Standardization

Indexed keywords

BETA2 GLYCOPROTEIN 1; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; AUTOANTIBODY; AUTOANTIGEN; DIAGNOSTIC KIT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD SAMPLING; CALIBRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROMETRY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PREGNANCY DISORDER; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; DIAGNOSTIC KIT; IMMUNOLOGY; STANDARD; STANDARDS;

ADULT; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; AUTOANTIGENS; BETA 2-GLYCOPROTEIN I; CALIBRATION; FEMALE; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; REAGENT KITS, DIAGNOSTIC; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY;

EID: 85013710631     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1093/AJCP/AQW065     Document Type: Article

References (29)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
2. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677-2686.
3. Day HM, Thiagarajan P, Ahn C, et al. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests. J Rheumatol. 1998;25:667-674.
4. Tubach F, Hayem G, Marchand JL, et al. IgG anti–beta2-glycoprotein I antibodies in adult patients with systemic lupus erythematosus: prevalence and diagnostic value for the antiphospholipid syndrome. J Rheumatol. 2000;27:1437-1443.
5. Cabral AR, Cabiedes J, Alarcon-Segovia D. Heterogeneity of antibodies to beta2-glycoprotein 1 from patients with systemic lupus erythematosus. Lupus. 2004;13:182-187.
6. Danowski A, Kickler TS, Petri M. Anti–beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol. 2006;33:1775-1779.
7. Locht H, Wiik A. IgG and IgM isotypes of anti-cardiolipin and anti–beta2-glycoprotein I antibodies reflect different forms of recent thrombo-embolic events. Clin Rheumatol. 2006;25:246-250.
8. Galli M. Interpretation and recommended testing for antiphospholipid antibodies. Semin Thromb Hemost. 2012;38:348-352.
9. 2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Lupus. 2012;21:764-765.
10. Reynaud Q, Lega JC, Mismetti P, et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2014;13:595-608.
11. Reber G, Tincani A, Sanmarco M, et al. Variability of anti–beta2 glycoprotein I antibodies measurement by commercial assays. Thromb Haemost. 2005;94:665-672.
12. Pengo V, Biasiolo A, Bison E, et al. Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti–beta2-Glycoprotein I activity. Thromb Res. 2007;120:127-133.
13. 2-glycoprotein I antibodies: normal reference ranges in northwestern Italy. Lupus. 2012;21:799-801.
14. 2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum. 2012;64:1-10.
15. Willis R, Harris EN, Pierangeli SS. Current international initiatives in antiphospholipid antibody testing. Semin Thromb Hemost. 2012;38:360-374.
16. 2glycoprotein antibody measurement. Lupus. 2014;23:1317-1319.
17. Petri M, Nelson L, Weimer F, et al. The automated modified Russell viper venom time test for the lupus anticoagulant. J Rheumatol. 1991;18:1823-1825.
18. Brandt JT, Triplett DA, Alving B, et al. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost. 1995;74:1185-1190.
19. Lockshin MD, Kim, Laskin CA, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum. 2012;64:2311-2318.
20. Forastiero R, Papalardo E, Watkins M, et al. Evaluation of different immunoassays for the detection of antiphospholipid antibodies: report of a wet workshop during the 13th International Congress on Antiphospholipid Antibodies. Clin Chim Acta. 2014;428:99-105.
21. Persijn L, Decavele AS, Schouwers S, et al. Evaluation of a new set of automated chemiluminescense assays for anticardiolipin and anti–beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Thromb Res. 2011;128:565-569.
22. Decavele AS, Schouwers S, Devreese KM. Evaluation of three commercial ELISA kits for anticardiolipin and anti–beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Int J Lab Hematol. 2011;33:97-108.
23. Audrain MA, Colonna F, Morio F, et al. Comparison of different kits in the detection of autoantibodies to cardiolipin and beta2glycoprotein 1. Rheumatology. 2004;43:181-185.
24. 2glycoprotein I antibodies: comparison between a home-made ELISA and a fluorescence enzyme immunoassay. Clin Chim Acta. 2015;446:93-96.
25. Villalta D, Alessio MG, Tampoia M, et al. Accuracy of the first fully automated method for anti-cardiolipin and anti–beta2 glycoprotein I antibody detection for the diagnosis of antiphospholipid syndrome. Ann N Y Acad Sci. 2009;1173:21-27.
26. Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118:4714-4718.
27. Ruffatti A, Tonello M, Visentin MS, et al. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology. 2011;50:1684-1689.
28. Reber G, Schousboe I, Tincani A, et al. Inter-laboratory variability of anti–beta2-glycoprotein I measurement: a collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost. 2002;88:66-73.
29. Nash MJ, Camilleri RS, Kunka S, et al. The anticardiolipin assay is required for sensitive screening for antiphospholipid antibodies. J Thromb Haemost. 2004;2:1077-1081.